Recent Updates
Recently added Catalysts
URGN Positive Sentiment

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

Monday, August 17, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: UroGen Pharma has announced the submission of a New Drug Application (NDA) for UGN-103, an investigational treatment aimed at recurrent LG-IR-NMIBC. This submission is a crucial milestone for the company as it seeks to advance its innovative cancer treatment solutions. The NDA submission reflects UroGen's commitment to addressing unmet medical needs in urothelial cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • UroGen has submitted an NDA for UGN-103.
  • The treatment targets recurrent LG-IR-NMIBC.
  • This submission marks a significant step in UroGen's development pipeline.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+188%
120-day peak, hindsight
Typical move
18.4%
average across 4 past catalysts
Lead asset
UGN-104
Phase 3 · Upper Urinary Tract Urothelial Carcinoma

Full Press Release Details

PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the submission of a New Drug Application (NDA) to the U.S.

Frequently Asked Questions

What is UGN-103?

UGN-103 is an investigational treatment developed by UroGen for recurrent LG-IR-NMIBC.

What type of application has UroGen submitted?

UroGen has submitted a New Drug Application (NDA) for UGN-103.

What does LG-IR-NMIBC stand for?

LG-IR-NMIBC stands for low-grade, intermediate-risk non-muscle invasive bladder cancer.

What is the significance of the NDA submission?

The NDA submission is a significant milestone for UroGen in advancing its cancer treatment solutions.

ShareAdd on Google
Tags: URGN Viatris Investor Conferences Healthcare UroGen Pharma UGN-103 NDA submission recurrent LG-IR-NMIBC urothelial cancer
Last updated: Aug 17, 2026

Biotech snapshot

Cash runway
$109M liquidity · $0M/mo burn
Low dilution risk
Lead asset
UGN-104Phase 3
Upper Urinary Tract Urothelial Carcinoma →

Catalyst track record

+188%
best trade around URGN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for URGN.

See every catalyst's timing & PoA →